Maze Therapeutics (NASDAQ:MAZE) Rating Increased to Strong-Buy at TD Cowen

Maze Therapeutics (NASDAQ:MAZE) was upgraded by equities research analysts at TD Cowen to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

Several other research firms have also commented on MAZE. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. BTIG Research reissued a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Stock Up 0.6%

Shares of NASDAQ MAZE opened at $29.60 on Monday. Maze Therapeutics has a one year low of $12.91 and a one year high of $53.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The firm’s 50 day simple moving average is $28.42 and its two-hundred day simple moving average is $32.27. The stock has a market capitalization of $1.64 billion, a P/E ratio of -11.75 and a beta of 2.22.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting the consensus estimate of ($0.76). As a group, analysts expect that Maze Therapeutics will post -2.72 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Atul Dandekar sold 7,500 shares of the business’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total transaction of $205,050.00. Following the transaction, the insider owned 26,250 shares in the company, valued at $717,675. The trade was a 22.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $27.61, for a total value of $445,680.62. Following the transaction, the chief marketing officer directly owned 16,142 shares of the company’s stock, valued at $445,680.62. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 108,110 shares of company stock valued at $3,057,531 over the last ninety days. 5.30% of the stock is owned by insiders.

Institutional Trading of Maze Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MAZE. California State Teachers Retirement System boosted its holdings in Maze Therapeutics by 54,096.5% in the second quarter. California State Teachers Retirement System now owns 777,720 shares of the company’s stock valued at $23,207,000 after acquiring an additional 776,285 shares in the last quarter. Frazier Life Sciences Management L.P. raised its holdings in Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after purchasing an additional 465,641 shares in the last quarter. AXQ Capital LP raised its holdings in Maze Therapeutics by 114.1% in the 2nd quarter. AXQ Capital LP now owns 15,193 shares of the company’s stock worth $453,000 after purchasing an additional 8,098 shares in the last quarter. Braidwell LP purchased a new stake in shares of Maze Therapeutics in the 2nd quarter worth about $34,019,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Maze Therapeutics by 4,054.3% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,739 shares of the company’s stock worth $529,000 after purchasing an additional 17,312 shares during the period.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.